| NCT ID | NCT02178722 |
| Title | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202) |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | yes |
| Sponsors | Incyte Corporation |
| Indications |
renal pelvis transitional cell carcinoma triple-receptor negative breast cancer urethra transitional cell carcinoma Her2-receptor negative breast cancer head and neck squamous cell carcinoma prostate transitional cell carcinoma endometrial transitional cell carcinoma fallopian tube transitional cell carcinoma ureter transitional cell carcinoma |
| Therapies | |
| Age Groups: | adult senior |